Seven-year "cure" of lung cancer with metastasis to the brain

Resection of single brain metastasis in non-small-cell lung cancer: prognostic factors

Combined resection of primary non-small-cell lung cancer and single brain metastasis is reportedly superior to other treatments in prolonging survival and disease-free interval. To identify prognostic factors that influenced survival we reviewed clinical records and follow-up data of 52 consecutive patients with non-small-cell lung cancer and single brain metastasis who had been evaluated for combined lung and brain operation: 19 had synchronous and 33 metachronous non-small-cell lung cancer and single brain metastasis. Seven patients were excluded from combined operation because of either early brain relapse after craniotomy or single brain metastasis localization in deep brain structures. Forty-one of the 45 patients who underwent combined operation had complete remission of neurologic symptoms. Actuarial 5-year survival from the second surgical intervention was 16% (median 19 months, range 1 to 104 months). N0 status and lobectomy were the only variables associated with longer survival. Actuarial 5-year survivals in patients with synchronous and metachronous presentation were 6.6% and 19%, respectively. In patients with metachronous presentation the length of survival was significantly associated with N0 status, lobectomy, and interval between lung and brain operation equal to or longer than 14.5 months. The subset of patients with N0 status and interval between operations longer than 14.5 months had a 61% 5-year survival. None of the patients with N1-2 disease and shorter interval between operations was alive at 20 months. These data indicate that prognostic factors may help to identify subsets of patients with markedly different outcomes after combined lung and brain operation.

Brain tumors

This synthesis of the literature on radiotherapy for brain tumors, ie, cancer originating in the central nervous system (CNS), is based on 81 scientific articles, including 25 randomized studies, 13 prospective studies, and 25 retrospective studies. These studies involve 11,081 patients. A more comprehensive chapter on brain tumors may be ordered from SBU. Curative treatment is not available for patients with highly malignant glioma (grades III and IV). Postoperative radiotherapy for highly malignant glioma extends patients' survival, with good quality of life, by several weeks to several months. Virtually all patients die from this disease. Although the clinical benefits from radiotherapy, measured as survival, appear to be modest, it is more effective than any chemotherapy tested thus far. The clinical effects of radiotherapy for highly malignant glioma are improved only marginally by altering factors such as absorbed dose, fractionation, irradiated tissue volume, radiation quality, or by adding radiosensitizing substances. Radiotherapy alone usually provides a clear but temporary improvement in patients with highly malignant glioma, hence it clearly has a palliative benefit. Postoperative radiotherapy for low-grade malignant gliomas (grades I and II) may extend survival. It also reduces tumor volume. No evidence shows that radiotherapy alone or postoperatively can lead to cure. In patients who have undergone subtotal meningioma resection, postoperative radiotherapy substantially reduces the risk for recurrence and extends life, and is thereby indicated. Radiotherapy is not indicated following macroscopic radical meningioma surgery. Patients with brain metastases experience rapid neurological improvement following radiotherapy to the whole brain, and this palliative effect often remains throughout the remainder of the patient's life. Palliative radiotherapy, often to large volumes of the CNS, is therefore motivated in a large proportion of the patient groups. In a smaller group of patients with solitary metastases, radiotherapy may be given postoperatively following radical neurosurgery. Life may be extended in this group, otherwise radiotherapy does not influence survival. Stereotactic radiotherapy of solitary, mainly spherical metastases in the brain is often superior to other known methods with respect to palliation and survival. The number of patients is, however, relatively small.

Solitary cerebral metastasis from lung cancer with very long survival: report of two cases and review of the literature

Solitary cerebral metastases from lung cancer are not uncommon clinical events. Whatever treatment is adopted, long-term survival is rare. Very rare indeed are reports of patients surviving the discovery of lung cancer and brain metastasis for 10 years or more. Indeed, only 16 cases have been reported to our knowledge. We report two further cases, stressing the importance of correct clinicopathological staging so that treatment may be conducted in the way most likely to ensure longer and better survival and, pending a therapeutic breakthrough, to increase the number of long-term survivors.

Treatment of lung cancer metastatic to the brain. Results of combined excision

Lung cancer with solitary metastasis to the brain has been treated by surgical resection of both lesions over a 25-year period. Survival was 55 per cent at 1 year and 31 per cent at 2 years. Mean survival was 2.3 years, surpassing the 6-month average survival with more conservative therapy. An aggressive surgical approach to lung cancer with solitary cerebral metastasis results in improved survival and a better quality of life.

Solitary cerebral metastasis from Wilms' tumor without pulmonary involvement

A 6-year-old boy presented with a solitary cerebral metastasis 5 years after nephrectomy for stage I Wilms' tumor. Chest x-ray and computed tomography scan were normal. The occurrence of cerebral metastasis without pulmonary involvement in Wilms' tumor has not been described before.

Long-term survival after brain metastasis from lung cancer

A case is reported of prolonged survival after lobectomy for large cell undifferentiated carcinoma of the lung and resection of metastatic carcinoma of the brain. The patient had survived 11 years 5 months after lung resection and 10 years 4 months after excision of brain metastasis. A review of the reports of another 12 patients who survived 5 years or longer after craniotomy, shows that the surgical excision of a single metastatic lesion of the brain with or without postoperative irradiation offers the best hope for prolonged survival.

Non-small cell lung cancer. Neuroresection of the solitary intracranial metastasis followed by radiochemotherapy

Fifteen selected patients with advanced intrathoracic non-small cell lung cancer and solitary metastasis were treated by a combined program including craniotomy, brain and chest irradiation, and systemic chemotherapy. One patient died because of cerebral hemorrhage after the operation. Five patients failed to achieve neurologic benefit. Nine patients improved their neurologic grading, and the median duration of improvement was 10 months (range, 1-26 months). The responses to systemic treatment were: one complete response, three partial responses, six stable disease responses, and four progressive disease responses. The overall median survival was 6 months from craniotomy and 12 months from diagnosis. Five patients became long survivors; they had a survival time ranging between 12 and 26 months after craniotomy. In conclusion, one third of patients had a satisfactory response to treatment; this outlines the value of the combined aggressive therapeutic approach also performed in patients who had a highly unfavorable prognoses.

Surgical treatment of primary lung cancer and solitary brain metastasis

Twenty patients with carcinoma of the lung and a brain metastasis have undergone combined lung and brain surgery, which was synchronous in five. There were no operative deaths. Survival from the first surgical intervention was less than one year (3-10 months) in four patients (20%), one to two years in four (20%) and more than two years (26-66 months) in five patients (25%). Seven patients (35%) are alive and well after an average period of three years and three months (15-66 months). Actuarial survival at five years is 33.6%. All patients had severe neurological symptoms and 18 (90%) had a complete remission. Our experience and data reported in the literature point to the effectiveness of combined lung and brain surgery in prolonging symptom free survival in patients with lung cancer and solitary brain metastasis.

Carcinoma of lung with a solitary cerebral metastasis. Surgical management and review of the literature

During the years 1975 to 1980, 10 male patients and 1 female, with ages ranging between 40 to 61 years, underwent combined resection of primary lung cancer and solitary brain metastasis. In 8 patients the lung cancer was diagnosed and treated first. In those patients, craniotomy for removal of a solitary brain metastasis was carried out 8 to 60 months (mean, 27 months) after excision of the lung tumor. In 3 patients, brain metastasis was diagnosed and treated first and lung excision followed, 2 to 4 weeks after craniotomy. The most common histologic type of the tumor was adenocarcinoma (63.6%). There were no operative deaths. Three patients survived less than 6 months after surgery and were considered as a failure of surgical treatment. Seven patients lived longer than 1 year and three of them are still alive with a follow-up period between 2 to 3 1/2 years after both operations. One of the patients underwent recently successfully second brain intervention for removal of recurrent histologically identical solitary brain metastasis and is well. Our results and those reported in literature encourage the combined surgical removal of primary lung cancer and a solitary brain metastasis.

Results of operative treatment of intracranial metastatic tumors

Survival and quality of survival have been investigated in 79 patients operated for intracranial metastatic tumor during the decade 1967--1977. The 30-day mortality was 10%. Median survival varied between two and 14 months depending upon the type of primary tumor. The one-year survival was 22% and the two-year survival was 10%. Duration of survival depended strongly upon type of primary turmor and little upon preoperative condition, age, or sex. Fifty-three percent of neurologically impaired patients who survived for at least one month were in better condition after surgery and 5% were in worse condition.

Surgical treatment of single brain metastasis: factors associated with survival

The results of surgical excision of solitary intracerebral metastases followed by whole-brain radiation therapy between 1972 and 1978 in a series of 78 patients were analyzed. The overall median survival of the series was 6 months with a 1-year survival rate of 29%. Statistical analyses of the data revealed that patients who presented with a cerebral metastasis 1 year or more after diagnosis of the primary cancer had a significantly longer survival than those in whom the metastasis was detected within 1 year (P less than .04). Patients with mild or no neurological deficits at time of craniotomy had a longer median survival and a 1-year survival of 44% (P less than .01). The presence of metastases at one or two other sites did not significantly affect overall survival except in those patients in whom the brain metastasis was detected more than 1 year after diagnosis of the primary tumor. Factors found to affect survival in this study may be useful in predicting survival of future patients similarly treated.

Surgical treatment of bronchogenic carcinoma with a brain metastasis

Twenty-three patients with bronchogenic carcinoma and a brain metastasis had their primary and secondary tumors treated surgically. The 10 men and 13 women had an average age of 52 years. Fifteen patients presented with a lesion of the lung and eight patients presented initially with neurological findings of an intracranial mass lesion. The most common histological type of tumor was adenocarcinoma (48%), followed by squamous cell carcinoma, undifferentiated small cell carcinoma, and bronchoalveolar carcinoma. Twelve patients (52%) had a poor result and died during the first six months. Surgery appeared to improve short-term survival in six patients (26%). Five patients (22%) had a good result and lived longer than 2 years without significant neurological deficit. Three patients (13%) are alive 10 or more years following surgery.